Researchers at Diagnostic Product Development, Exiqon A/S based in Vedaek, Denmark, report a new micro RNA screen assay detected the majority of early-stage colorectal cancers.
"Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup," Soren Jensby Nielsen says in a statement. "We envision that this type of miRNA profile, once developed and marketed as a screening kit, can be used to screen entire populations in order to facilitate a focused selection of individuals who should undergo colonoscopy."
Nielsen presented the findings at the American Association for Cancer Research Fourth International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Dallas.
Megyn Kelly: Santa Claus and Jesus are both white men
Costly malfunction causes beer flood at Boston-area brewery